FP&A Manager at Axsome Therapeutics Inc

San Diego, California, United States

Apply Now

$89,000 – $112,000Compensation

Mid-level (3 to 4 years), Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, PharmaceuticalsIndustries

Requirements

Bachelor’s degree in Accounting, Finance, Economics, or a related discipline preferred. Equivalent work experience will be considered; MBA or CPA a plus
5-8 years of professional FP&A experience within biotech, pharma or life sciences. Prior experience in investment banking, public accounting, or management consulting is a plus
Strong understanding of R&D life cycles, preclinical drug discovery and development processes, and associated cost drivers
Advanced Excel and financial modeling skills; prior experience with enterprise resource planning (ERP) systems (e.g. NetSuite) and financial planning tools (e.g. Adaptive Planning, Anaplan, or similar) is preferred
Strong communication and presentation skills required, with the ability to partner effectively across scientific and business teams
Ability to prioritize, coordinate and handle multiple projects to meet deadlines
Self-motivated and strong desire to build new processes and tools to support a growth-oriented organization
Strong analytical mindset, attention to detail, and ability to thrive in a fast-paced, dynamic environment are required

Responsibilities

Serve as primary finance business partner for all Discovery and Preclinical groups including Chemistry, Biology, DMPK, Computational Science, Analytical, and HTE & Lab Operations
Lead the financial planning process (annual planning cycle, mid-year reforecast and quarterly budget-to-actual meetings) for all Discovery and Preclinical groups
Develop and maintain robust financial models and budgets to track all spending by group, program, and project, and detailed headcount plans
Provide timely and actionable financial insights to senior leadership in support of strategic decision-making
Assist in long-range planning efforts as well as scenario planning initiatives for our internal pipeline and external partnership programs
Collaborate with the Accounting team on month-end close activities, including preclinical and other accruals
Support the development of scalable, gold-standard FP&A tools, systems and processes as the company grows
Identify and recommend opportunities for process improvements and efficiency enhancements within the FP&A function
Work effectively as a team contributor on all assignments, as well as independently, while understanding the necessity for communicating and coordinating work efforts with colleagues across the organization
Perform ad hoc analysis and special projects, as assigned

Skills

FP&A

Financial Planning

Forecasting

Financial Modeling

Budgeting

Variance Analysis

Scenario Planning

Accruals

Excel

Month-End Close

Axsome Therapeutics Inc

Develops therapies for CNS disorders

About Axsome Therapeutics Inc

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

New York City, New YorkHeadquarters

2012Year Founded

$430.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Performance Bonus

Company Equity

Risks

Increased competition from companies like Compass Pathways in the CNS market.

Potential delays in AXS-07 launch amid growing market anticipation.

Departure of key personnel like Lori Englebert may impact strategic direction.

Differentiation

Axsome focuses on CNS disorders with limited current treatment options.

AXS-05, an NMDA receptor antagonist, targets major depressive disorder and treatment-resistant depression.

Axsome's balanced portfolio includes both clinical and research stage products.

Upsides

FDA's fast-tracking of CNS treatments could expedite Axsome's drug approvals.

Increased investment in CNS R&D drives innovation, benefiting Axsome's pipeline.

Growing personalized medicine trend offers Axsome opportunities for tailored therapies.

Land your dream remote job 3x faster with AI

Try Jobo Free